Recombinant CA19-9 Antibody [CA19.9/1390R]

• Background:

  CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens.

• Swiss Prot:

  NotKnown

• Host:

  Rabbit

• Reactivity:

  Human

• Immunogen:

  Purified human protein used as the immunogen for the recombinant CA19-9 antibody.

• Clonality:

  Recombinant Monoclonal

• Clone:

  CA19.9/1390R

• Conjugation:

  Unconjugated

• Type:

  Primary Antibodies

• Field of Research:

  Cancer

• Purification:

  Protein A affinity

• Concentration:

  0.2 mg/mL

• Buffer:

  PBS with 0.1 mg/ml BSA and 0.05% sodium azide

• Modification:

  None

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.

• Fragment:

  IgG, k

• Applications Notes:

  1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

• Tested Applications:

  WB, Flow, IF, IHC-P

• Physical Properties:

  Liquid